On July 27, 2020 Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, reported that interim results from the ongoing Phase 2 ACCURACY clinical trial of AL101 for the treatment of recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harbouring Notch activating mutations will be presented in an oral presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Virtual Congress 2020, being held September 19-September 21, 2020 (Press release, Ayala Pharmaceuticals, JUL 27, 2020, View Source [SID1234563989]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral presentation information is as follows:

Title: ACCURACY a Phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)
Session Title: Mini Oral Presentation
Session Date and Time: September 18, 2020, 03:55 CEST
Presentation Number: 919MO
Presenter: Renata Ferrarotto, MD, MD Anderson Cancer Center

The presentation will be available to registrants of the ESMO (Free ESMO Whitepaper) Virtual Congress 2020 at 03:55 CEST on September 18, 2020. The presentation will be archived under "Events and Presentations" in the Investors section of Ayala’s website at ir.ayalapharma.com.

On July 27, 2020 Immodulon, the immuno-oncology company, reported an expansion to its ongoing collaboration with Professor van Eijck and his team at the Erasmus University Medical Center Rotterdam ("Erasmus MC") (Press release, Immodulon Therapeutics, JUL 27, 2020, View Source [SID1234562740]). A phase I/II, open label study is being planned in patients with limited metastatic pancreatic cancer ("MEPANC -1") . The trial is designed to evaluate the safety and efficacy of IMM-101 administered in combination with stereotactic radiotherapy of metastases in the liver and lung in patients with limited metastatic pancreatic cancer. This follows the successful recruitment of 20 patients in a separate phase I/II study combining IMM-101 with stereotactic radiotherapy in locally advanced pancreatic cancer ("LAPC-2"). The MEPANC -1 study design will be submitted to the local Erasmus MC Medical Ethics Review Committee and the national Central Committee on Research Involving Human Subjects(CCMO) and, should it be approved, recruitment is expected to begin by the end of 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Professor Casper H J van Eijck, hepatobiliary surgeon and Professor in surgery, commented:
"We look forward to starting this new original study which has not been performed before in patients with limited metastatic pancreatic cancer. Since the recruitment in the LAPC-2 study is highly successful, we expect to include patients from all Dutch Pancreatic Cancer Group hospitals within the allocated time frame. We are pleased that Immodulon is providing us with the IMM-101 study drug again and their support and hope that combining IMM-101’s positive effects on the immune system in combination with radiotherapy will lead potentially to a major step forward in the search of new and effective treatments for pancreatic cancer."

Dr. Jaap Kampinga, Chief Executive Officer of Immodulon, commented:
"We are pleased with the progress of our collaboration with Professor van Eijck and his team at this Centre of Excellence for pancreatic cancer at Erasmus MC. The MEPANC -1 study, testing our lead drug candidate, IMM-101, in limited metastatic pancreatic cancer, is designed to complement the ongoing LAPC-2 study. We look forward to the potential initiation of the MEPANC -1 study before the end of 2020, pending approval from local and national regulatory authorities. Pancreatic cancer is a devasting disease and remains exceedingly challenging to treat effectively, despite the advances in other cancer treatments."

On July 27, 2020 Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, reported that it has raised £0.75 million (before expenses) pursuant to a Broker Option following the completion of the UK Placing (Press release, Midatech Pharma, JUL 27, 2020, View Source [SID1234562695]). The result of the UK Placing of 18,518,518 Placing Shares at an Issue Price of £0.27 per share was announced earlier today. The UK Placing was significantly oversubscribed and brings new UK institutions into the Company’s shareholder base.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company granted an option to Turner Pope under the Placing Agreement to enable them to deal with additional demand under the UK Placing in the event that requests to participate in the UK Placing from qualifying investors were received during the period from the time of the announcement of the UK Placing to 8.00 a.m. on 27 July 2020 up to a maximum of £0.75 million. Turner Pope has exercised the Broker Option to the maximum extent in respect of 2,777,777 Broker Option Shares at the same price as the UK Placing.

Accordingly, the total number of New Ordinary Shares to be issued by the Company pursuant to the UK Placing and the Broker Option is 21,296,295. The aggregate gross proceeds of the UK Placing and the Broker Option is £5.75 million. Aggregate proceeds, net of expenses, are expected to be £5.28 million.

Application for Admission to trading on AIM

Subject to all conditions being met, application will be been made for 21,296,295 New Ordinary Shares to be admitted to trading on AIM. It is expected that settlement of the Placing Shares and the Broker Option Shares and Admission will take place at 8.00 a.m. on or about 3 August 2020 and that dealings in the Placing Shares and, if applicable, the Broker Option Shares will commence at that time.

When issued the New Ordinary Shares will be fully paid and will rank pari passu in all respects with the existing Ordinary Shares.

Total Voting Rights

The Company’s issued share capital following the issue of equity noted above, will comprise 60,548,852 ordinary shares of 0.1p each with voting rights. The Company does not hold any shares in treasury. This figure of 60,548,852 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

Capitalised terms used in this announcement have the meanings given to them in the announcement of the UK Placing earlier today.

Commenting, Stephen Stamp, Midatech CEO and CFO, said: "I am delighted with the result of the UK Placing and welcome on board our new shareholders. The oversubscription of the UK Placing followed by full take-up of the Broker Option is a massive vote of confidence in our new strategy and the progress we have made since we started our strategic review in April."

On July 27, 2020 TCR2 Therapeutics Inc. (Nasdaq: TCRR) ("TCR2" or the "Company"), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, reported that it has commenced an underwritten public offering of 6,000,000 shares of its common stock (Press release, TCR2 Therapeutics, JUL 27, 2020, View Source [SID1234562645]). TCR2 also intends to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock. All of the shares in the proposed offering are to be sold by TCR2. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies, SVB Leerink, Piper Sandler and BMO Capital Markets are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey is acting as co-manager for the offering.

TCR2 intends to use the net proceeds of the offering to advance its clinical and earlier stage programs and for research and development, working capital and general corporate purposes.

The securities described may be offered pursuant to a shelf registration statement on Form S-3 (File No. 333-236965), including a base prospectus that was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on April 28, 2020. The proposed offering will be made only by means of a prospectus. A preliminary prospectus supplement and a final prospectus supplement relating to, and describing the terms of, this offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the preliminary prospectus may also be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Departments, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by phone at (877) 821-7388, or by email at [email protected]; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, by email at [email protected], or by phone at (800) 808-7525, ext. 6218; Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by email at [email protected], or by phone at (800) 747-3924; or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, 25th Floor, New York, NY 10036, by email at [email protected], or by phone at (800) 414-3627.

Important Information

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any offer or sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On July 27, 2020 Lynk Pharmaceuticals (Hangzhou, China) reported that exclusive licensing agreements with Kobe University (Kobe, Japan) and with RIKEN Research Institute (Saitama, Japan) to develop RAS inhibitors with a novel MOA (Press release, Lynk Pharma, JUL 27, 2020, View Source [SID1234562459]). The agreement with Kobe University also includes a joint collaboration which will continue to provide screening and structural support.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RAS has been identified as a key driver in numerous cancers including pancreatic (95%), colon (50%) and lung adenocarcinomas (30%). RAS was first identified in the 1960’s and has been targeted for over 35 years with only limited success. While recent progress made by irreversible binding towards KRAS G12C subset, this approach cannot inhibit other more dominant KRAS mutants such as G12V and G12D.

Built on Kobe University and RIKEN’s early structural biology and screening outcome, Lynk Pharmaceuticals will utilize its medicinal chemistry and drug design expertise to develop RAS inhibitors with desirable properties to target a broader range of undruggable RAS onco-drivers and ultimately develop the compounds for clinical use. "This is a very ambitious approach for us to challenge a decades-old undruggable target, but we believe our approach, with an exciting novel mechanism of action, will bring better hope to the patients by jointing hands with two reputed research organizations in the world," said Dr. Zhao-Kui (ZK) Wan, Founder, Chairman and CEO of Lynk.